|
A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients with Late-Stage HIV Disease Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients with Late-Stage HIV Disease conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients with Late-Stage HIV Disease Clinical research trials and A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients with Late-Stage HIV Disease medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients with Late-Stage HIV Disease. A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients with Late-Stage HIV Disease Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients with Late-Stage HIV Disease clinical trial. Subjects often receive the most expert healthcare possible for their A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients with Late-Stage HIV Disease condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients with Late-Stage HIV Disease A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients with Late-Stage HIV Disease
A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients with Late-Stage HIV Disease
For Condition: HIV Infections
Status: Completed
Sponsor(s): OXO Chemie ,
Synopsis: The purpose of this study is to see if it is safe and effective to give WF10 to adults with late-stage HIV disease. WF10 is suspected to help the immune system fight infection and slow HIV disease progression.
Details: Patients are randomized to 1 of 2 treatment groups to receive 4 IV treatment cycles of either WF10 or control (physiological saline solution). Patients are monitored throughout the study for: a) clinical progression; b) number, duration, and cause of hospitalizations; c) quality of life; and d) density of CD38 antigen on CD8+ T cells. Patients receive treatment for 11 weeks but will continue to be followed for a maximum of 96 weeks. During the follow-up period, patients are evaluated initially at Week 18, then at Weeks 24, 36, and 48. If the study is continued beyond Week 48, follow-up visits are conducted at Weeks 72 and 96.
Eligibility:
Study Type: Interventional, Treatment, Double-Blind, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients may be eligible for this study if they: - Are HIV-positive. - Have a CD4 cell count of less than 50 cells/mm3 within 14 days prior to study entry. - Are at least 18 years old. - Have received anti-HIV drugs at some time in the past. - Agree to practice abstinence or use effective methods of birth control, including the pill, during the study. Exclusion Criteria Patients will not be eligible for this study if they: - Are being treated for any form of cancer within 30 days of study entry. - Have ever received an HIV vaccine. - Have received steroids within 30 days prior to study entry. (Note: Testosterone is allowed.) - Have received certain medications, including anti-HIV treatments that are not approved by the FDA. - Have participated in another WF10 study. - Have an illness or any condition that might exclude them from this study. - Are pregnant or breast-feeding. - Abuse drugs or medications. - Received a blood transfusion within 45 days prior to study entry.
Total Enrollment: 240
Location and Contact Information:
Associates in Med and Mental Health
Tulsa, Oklahoma, 74114
United States
Montreal Gen Hosp / Div of Clin Immuno and Allergy
Montreal, Quebec,
Canada
The CORE Ctr
Chicago, Illinois, 60612
United States
Univ of Alabama at Birmingham
Birmingham, Alabama, 35294
United States
Truman Med Ctr / Infectious Disease Clinic
Kansas City, Missouri, 64108
United States
Newark Community Health Ctr
Newark, New Jersey, 07114
United States
MCP Hahnemann Univ
Philadelphia, Pennsylvania, 19102
United States
Virginia Mason Research Center / Clinical Trial Unit
Seattle, Washington, 98101
United States
Leahi Hosp / Univ of Hawaii
Honolulu, Hawaii, 96816
United States
Regions Hosp
St. Paul, Minnesota, 55101
United States
St Paul's Hosp
Vancouver, British Columbia,
Canada
Boston Med Ctr / Clinical Research Office
Boston, Massachusetts, 02118
United States
UCSF - San Francisco Gen Hosp
San Francisco, California, 94110
United States
Univ of Miami School of Medicine
Miami, Florida, 33136
United States
Highland Gen Hosp / San Francisco Gen Hosp
Oakland, California, 946021018
United States
George Washington Univ Med Ctr
Washington D.C., District of Columbia, 20037
United States
Ludwig Lettau Private Practice
Charleston, South Carolina, 29414
United States
Sunnybrook Health Science Ctr
Toronto, Ontario,
Canada
Ctr for Quality Care
Tampa, Florida, 33609
United States
Tower Infectious Disease Med Ctr
Los Angeles, California, 90048
United States
QEII Health Science Centre
Halifax, Nova Scotia,
Canada
Univ Health Ctr
Detroit, Michigan, 48201
United States
Rush Med Ctr / Section of Infectious Diseases
Chicago, Illinois, 60612
United States
Ottawa General Hospital
Ottawa, Ontario,
Canada
Hillsborough County Health Dept
Tampa, Florida, 33602
United States
Hampton Roads Med Specialists
Hampton, Virginia, 23666
United States
Northwestern Univ Med School
Chicago, Illinois, 60611
United States
Univ of Iowa Hosp & Clinic
Iowa City, Iowa, 52242
United States
Burnside Clinic
Columbia, South Carolina, 29206
United States
AIDS Research Consortium of Atlanta
Atlanta, Georgia, 30308
United States
Univ of New Mexico Health Science Center
Albuquerque, New Mexico, 87131
United States
ViRx Inc
San Francisco, California, 94103
United States
Additional Information:
Study ID Numbers: 222C;
Study Start Date:
Record last reviewed: March 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002244
Other Hiv Infections Studies:
1. Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment
2. The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients with AIDS
3. A Study of Indinavir Taken with or without DMP 266
4. Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV
5. Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use with Certain Anti-HIV Drugs in HIV-Infected Women
Related Studies:
Other HIV Infections Clinical Trials
Other Washington Clinical Trials
Other Seattle Clinical Trials
A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients with Late-Stage HIV Disease
|
|
|
|
|
|
|
|